Last reviewed · How we verify
Micro-K 10 (POTASSIUM CHLORIDE)
Micro-K 10 works by replenishing potassium levels in the body, which helps regulate muscle and nerve function.
Micro-K 10 is a potassium chloride medication originally developed by HOSPIRA and currently owned by Nesher Pharms. It is a small molecule that targets carbonic anhydrase 4 and is classified as a potassium chloride drug. Micro-K 10 is FDA-approved for treating constipation, hypokalemia, hypokalemia prevention, and incomplete passage of stool. The medication is off-patent, with 56 generic manufacturers available. As a potassium supplement, it is essential to monitor potassium levels and renal function in patients taking Micro-K 10.
At a glance
| Generic name | POTASSIUM CHLORIDE |
|---|---|
| Sponsor | Nesher Pharms |
| Drug class | potassium chloride |
| Target | Carbonic anhydrase 4 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1965 |
Mechanism of action
Metabolic Acidosis Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.
Approved indications
- Constipation
- Hypokalemia
- Hypokalemia Prevention
- Incomplete passage of stool
Common side effects
- nausea
- vomiting
- flatulence
- abdominal pain/discomfort
- diarrhea
Drug interactions
- Triamterene or amiloride
- Renin-angiotensin-aldosterone inhibitors (e.g., ACE inhibitors, ARBs, spironolactone, eplerenone, aliskiren)
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Key clinical trials
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE4)
- Saccharin and Acesulfame Potassium Consumption and Glucose Homeostasis in Older Adults With Prediabetes (NA)
- FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants) (NA)
- A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (PHASE4)
- Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection (PHASE1)
- Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited Potassium Content in Patients With Chronic Kidney Disease: A Pilot Study (NA)
- Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (PHASE4)
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 12539314 | 2039-03-07 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Micro-K 10 CI brief — competitive landscape report
- Micro-K 10 updates RSS · CI watch RSS
- Nesher Pharms portfolio CI